Who Owns Johnson & Johnson Company?

Johnson & Johnson Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Johnson & Johnson?

Unraveling the ownership structure of Johnson & Johnson, a healthcare behemoth, is key to understanding its strategic maneuvers and market influence. The 2023 spin-off of its Consumer Health division into Kenvue dramatically reshaped the company's landscape, making it a fascinating case study in corporate evolution. This deep dive will explore the shifts in Johnson & Johnson SWOT Analysis, from its founding family to today's institutional investors.

Understanding who owns the Johnson and Johnson company is critical for investors and stakeholders alike. Knowing the Johnson & Johnson parent company and its major J&J shareholders provides insights into its governance, strategic direction, and long-term value. This analysis will examine the impact of the company's ownership on its performance and future prospects, including the roles of Johnson & Johnson executives and the board of directors.

The story of the company begins in 1886, with the vision of three brothers: Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson. Their goal was to capitalize on the advancements in antiseptic surgery pioneered by Joseph Lister. This led to the establishment of a company focused on producing sterile surgical supplies and household products.

Robert Wood Johnson I took the helm as the first president, and the company was officially incorporated in 1887. Their initial product line included essential medical supplies such as sutures, absorbent cotton, and gauze. These products marked a significant step forward in medical hygiene, setting the stage for the company's future growth.

While the exact initial ownership percentages are not publicly available, the founding brothers played a crucial role in shaping the early success of the company. The well-known logo is a replica of James Wood Johnson's signature. Edward Mead Johnson later left to start his own company, Mead Johnson & Company, which is no longer affiliated with the company.

Founding and Incorporation

The company was founded in 1886 by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson. It was formally incorporated in 1887.

Early Products

Early products included sutures, absorbent cotton, and gauze. These were significant advancements in medical hygiene.

Leadership Transition

Robert Wood Johnson I was the first president. Leadership transitioned to James Wood Johnson and later to Robert Wood Johnson II.

Edward Mead Johnson's Departure

Edward Mead Johnson left to establish Mead Johnson & Company in 1905. This company is not affiliated with the company today.

Logo Origin

The company's logo is a replica of James Wood Johnson's signature.

Family Leadership

The Johnson family maintained leadership for several decades. Their direct control diminished after the initial public offering.

The evolution of the company's ownership reflects its growth from a family-run business to a publicly traded multinational corporation. Understanding the target market of Johnson & Johnson provides further insight into the company's strategic direction. The company, now a global entity, has a substantial market capitalization, with its shares traded on the New York Stock Exchange under the ticker JNJ. As of late 2024, the company's market capitalization is over $400 billion, underscoring its significant presence in the healthcare sector. The company's board of directors is responsible for overseeing the strategic direction of the company, ensuring that the interests of the shareholders are represented. The company's success is reflected in its consistent revenue and profitability, with annual revenues exceeding $85 billion in recent years. The company operates in diverse sectors, including pharmaceuticals, medical devices, and consumer health products. The major shareholders of the company include institutional investors, who hold a significant portion of the outstanding shares. The company's headquarters are located in New Brunswick, New Jersey. The company's subsidiaries span across various countries, contributing to its global footprint. The company's annual reports provide detailed financial information and insights into its operations. The current CEO and other Johnson & Johnson executives play a crucial role in the company's day-to-day operations.

Johnson & Johnson SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The evolution of Johnson & Johnson's ownership structure has been marked by significant milestones. The company transitioned to a publicly listed entity in 1944 through an Initial Public Offering (IPO) on the New York Stock Exchange (NYSE), with shares priced at $37.50. This marked the beginning of a shift away from direct family control, culminating in Robert Wood Johnson II's departure as the last family member to lead the company in 1963. Today, understanding the dynamics of Johnson & Johnson ownership is crucial for investors and stakeholders alike.

A pivotal strategic move impacting the ownership landscape was the spin-off of the Consumer Health business into Kenvue in 2023. This strategic decision, aimed at streamlining operations and focusing on higher-growth segments, resulted in Kenvue's IPO in May 2023. Initially, Johnson & Johnson held a controlling stake, which was subsequently reduced through an exchange offer and complete divestiture in 2024. This demonstrates how strategic decisions can significantly reshape the company's structure and impact shareholder value. For more insights into the company's past, you can read a Brief History of Johnson & Johnson.

Currently, J&J shareholders are predominantly institutional investors, who collectively hold a substantial majority of the outstanding shares. As of December 2024, institutional investors held 73.57% of outstanding shares, a figure that remained largely unchanged at 72.85% as of May 2025. Key institutional investors include The Vanguard Group, Inc. (9.67% as of December 2024; 233,962,679 shares as of March 31, 2025), BlackRock, Inc. (8.36% as of December 2024; 199,366,959 shares as of March 31, 2025), and State Street Corporation (5.58% as of December 2024; 133,789,785 shares as of March 31, 2025). These institutions' trading actions significantly influence the company's stock price and policy.

Key Takeaways on Johnson & Johnson Ownership

The ownership of Johnson and Johnson company is primarily held by institutional investors, with a small percentage held by individual investors and minimal insider holdings.

• Institutional investors hold a substantial majority of shares, influencing company policy.
• The spin-off of Kenvue was a major strategic move impacting ownership.
• Understanding Who owns J&J is crucial for investors.
• The largest shareholders include The Vanguard Group and BlackRock.

Johnson & Johnson PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of December 2024, the Board of Directors of the company includes Joaquin Duato, serving as Chairman and Chief Executive Officer, alongside other directors such as Darius Adamczyk, Mary C. Beckerle, and Jennifer A. Doudna. The board also includes Marillyn A. Hewson, Paula A. Johnson, Hubert Joly, Mark B. McClellan, Anne M. Mulcahy, Mark A. Weinberger, Nadja Y. West, and Eugene A. Woods. This structure combines the roles of Chairman and CEO, supported by a Lead Director, to ensure clear leadership and independent oversight.

The leadership structure aims for accountability and effective governance. The Lead Director plays a critical role in facilitating independent oversight, ensuring that the board can effectively challenge management and represent shareholder interests. This approach is designed to maintain a balance between executive leadership and independent oversight, which is crucial for long-term value creation.

The company operates under a one-share-one-vote structure, meaning voting power directly reflects share ownership. While no single entity holds a majority stake, institutional investors wield significant influence. For instance, The Vanguard Group held 9.67%, BlackRock held 8.36%, and State Street Corporation held 5.58% of outstanding shares as of December 2024. These major shareholders significantly influence the company's direction and governance.

Shareholder Influence and Governance

Shareholders play a vital role in the company's governance, especially large institutional investors.

• The 2025 Annual Meeting of Shareholders was held virtually on April 24, 2025.
• All 11 Director nominees were elected.
• Executive compensation policies were approved.
• PricewaterhouseCoopers LLP was ratified as the independent auditor for 2025.

Johnson & Johnson Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

In recent years, the ownership profile of Johnson & Johnson has seen significant shifts, most notably with the spin-off of its Consumer Health business, which is now known as Kenvue. This strategic move, completed in 2024, allowed Johnson & Johnson to concentrate on its core strengths: innovative medicine and medical technology. The full divestiture of Kenvue generated $13.2 billion in cash proceeds and reduced the company's outstanding shares by approximately 7% in a tax-free manner. This restructuring aims to streamline operations and enhance shareholder value for J&J shareholders.

The company has also been actively involved in mergers and acquisitions, particularly within its pharmaceutical and MedTech segments. In 2024 and early 2025, Johnson & Johnson announced several key acquisitions, including Ambrx Biopharma, Shockwave Medical, Proteologix, and the planned acquisition of Intra-Cellular Therapies. These strategic investments reflect a broader industry trend of consolidation and a focus on high-growth areas. Furthermore, the company's capital allocation strategy includes share buybacks, with $2.13 billion in buybacks for the quarter ending March 31, 2025, and $2.432 billion in 2024. The consistent increase in dividends, marking its 62nd consecutive year in 2024 with a 4.2% increase to $4.96 per share, also reflects its commitment to returning value to shareholders.

Ownership trends show a high degree of institutional ownership, which stood at 72.85% as of May 2025. This level of institutional backing means that Johnson & Johnson's stock price is highly sensitive to the trading activities of these major investors. While insider ownership remains low at 0.03% as of May 2025, the influence of large institutional investors remains paramount. These strategic actions by the Johnson & Johnson parent company are geared towards achieving sustained growth and delivering value to shareholders. For more insights into their strategic direction, consider reading about the Growth Strategy of Johnson & Johnson. The company projects revenue growth of 5%-7% for the period of 2025-2030, showing confidence in its refocused portfolio.

Key Acquisition

In January 2024, Johnson & Johnson acquired Ambrx Biopharma for $2 billion, expanding its pharmaceutical portfolio.

Key Acquisition

The acquisition of Shockwave Medical in April 2024, for $13.1 billion, bolstered its MedTech segment.

Key Acquisition

In May 2024, Johnson & Johnson acquired Proteologix for $850 million, further expanding its portfolio.

Key Acquisition

In January 2025, Johnson & Johnson announced its intention to acquire Intra-Cellular Therapies for approximately $14.6 billion, emphasizing its focus on neuroscience.

Johnson & Johnson Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs